June 14th, 2021
•A highly accurate in vitro high-throughput assay system was developed to evaluate anticancer drugs using patient-derived tumor organoids (PDOs), similar to cancer tissues but are unsuitable for in vitro high-throughput assay systems with 96-well and 384-well plates.
Related Videos
High-sensitivity Detection of Micrometastases Generated by GFP Lentivirus-transduced Organoids Cultured from a Patient-derived Colon Tumor
Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells
Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids
Drug Screening of Primary Patient Derived Tumor Xenografts in Zebrafish
Creating Matched In vivo/In vitro Patient-Derived Model Pairs of PDX and PDX-Derived Organoids for Cancer Pharmacology Research
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Generation and Culturing of High-Grade Serous Ovarian Cancer Patient-Derived Organoids
Establishment and Culture of Patient-Derived Breast Organoids
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
Copyright © 2024 MyJoVE Corporation. 판권 소유